Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 8/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366380 | 1.00 | KLKB1 (0.43) | KLKB1ATRL3MBTL1GFERHSD17B10 | |
| SCHEMBL17785326 | 0.90 | KCNH2 (0.40) | KLKB1ATRL3MBTL1GFERHSD17B10 | |
| SCHEMBL21455353 | 0.86 | ATR (0.44) | KLKB1ATRL3MBTL1AAK1SSTR4 | |
| SCHEMBL30564617 | 0.83 | L3MBTL1 (0.41) | ATRL3MBTL1AAK1SSTR4NAMPT | |
| SCHEMBL31438501 | 0.83 | L3MBTL1 (0.41) | ATRL3MBTL1AAK1SSTR4NAMPT | |
| SCHEMBL29023442 | 0.81 | ATR (0.41) | ATRL3MBTL1AAK1SSTR4NAMPT | |
| SCHEMBL25198671 | 0.81 | ATR (0.43) | ATRL3MBTL1AAK1SSTR4NAMPT | |
| SCHEMBL27033926 | 0.80 | MTNR1A (0.50) | KLKB1AAK1SSTR4 | |
| SCHEMBL31352678 | 0.79 | SSTR4 (0.44) | ATRL3MBTL1SSTR4NAMPTKDM4A | |
| SCHEMBL18764702 | 0.77 | NAMPT (0.46) | KLKB1L3MBTL1NAMPTKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673437-A1 | NEW SOLID FORM OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-20250281397-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2025-09-11 | — | — | US | disclosed |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2025-03-06 | — | — | US | disclosed |
| EP-4480545-A2 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024180100-A1 | NEW SOLID FORM OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-09-06 | — | — | WO | disclosed |
| EP-4288036-B1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LTD (GB) | 2024-08-07 | — | — | EP | disclosed |
| US-20240199573-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | DRI UK LP (KY) | 2024-06-20 | — | — | US | disclosed |
| CN-118078821-A | Treatment of vascular oedema | 卡尔维斯塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240122909-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | DRI UK LP (KY) | 2024-04-18 | — | — | US | disclosed |
| EP-4291186-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | Kalvista Pharmaceuticals Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| EP-3224256-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| EP-3464271-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464265-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1 -YL)METHYL]PHENYL} METHYL) PYRAZOLE -4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2018-11-08 | — | — | US | disclosed |
| WO-2017207983-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017208005-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1 -YL)METHYL]PHENYL} METHYL) PYRAZOLE -4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| EP-3224256-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083820-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ATR 4106/4885L3MBTL1 1915/4885 |
| US-20240122909-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | SERPINB1, SERPINH1, SERPINE1 | KLKB1 4/4885ATR 4759/4885L3MBTL1 2410/4885 |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885ATR 3419/4885L3MBTL1 1930/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ATR 4106/4885L3MBTL1 1915/4885 |
| US-20250281397-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK5, KLK1 | KLKB1 1/4885ATR 3635/4885L3MBTL1 4017/4885 |
| US-20240199573-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | CYP3A4, CYP4B1, TPMT | KLKB1 4305/4885ATR 3917/4885L3MBTL1 3733/4885 |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ATR 4111/4885L3MBTL1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.